Subtype
Breast Adenocarcinoma
CI-CAN-00002035Explore in graph →
686 active trials9 approved drugs104 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002035Explore in graph →
Clinical trials
1,713 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (278)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03358017 | Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer(YAPPETIZER) | completed | Phase 2 | 54 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT01622868 | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH |
| 3 |
| Oct 17, 2023 |
| clinicaltrials |
| NCT01628536 | A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ | completed | N/A | 33 | Yale UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT03121352 | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03953833 | B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer(B003-101) | completed | Phase 1 | 30 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Sep 14, 2023 | clinicaltrials |
| NCT04032080 | LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer | completed | Phase 2 | 10 | Baylor Research InstituteOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT04081389 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05367739 | Real World Study on the Efficacy and Safety of Anti-HER2 Therapy | completed | — | 200 | Hunan Cancer HospitalOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05769751 | A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer | completed | — | 865 | Daiichi SankyoINDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer(HER2CLIMB) | completed | Phase 2 | 612 | Seagen Inc.INDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT02637024 | Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation(OPAR) | completed | Phase 2 | 280 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05071677 | Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer | completed | — | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT03193853 | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 12 | Joyce O'ShaughnessyOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT04022772 | Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer | completed | N/A | 287 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05730010 | Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis | completed | — | 289 | Indiana UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05961280 | Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates | completed | — | 385 | Gangnam Severance HospitalOTHER | 0 | Jul 27, 2023 | clinicaltrials |
| NCT02121873 | The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage | completed | — | 6 | Atossa Therapeutics, Inc.INDUSTRY | 1 | Jul 20, 2023 | clinicaltrials |
| NCT03599453 | Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | completed | Early Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01837602 | cMet CAR RNA T Cells Targeting Breast Cancer | completed | Phase 1 | 6 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02673398 | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | completed | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03872791 | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT02768701 | Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT02526498 | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery(TRIUMPH-T) | completed | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02531425 | Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC(TNBC) | completed | Phase 1 | 10 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04857697 | Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer | completed | Early Phase 1 | 6 | Mayo ClinicOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT01417286 | Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer | completed | Phase 2 | 69 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03775850 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | completed | Phase 1 | 69 | Evelo Biosciences, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT04584112 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | completed | Phase 1 | 83 | Hoffmann-La RocheINDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT01969643 | A Safety Study of SGN-LIV1A in Breast Cancer Patients | completed | Phase 1 | 290 | Seagen Inc.INDUSTRY | 1 | Mar 7, 2023 | clinicaltrials |
| NCT05754047 | Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients | completed | — | 3,582 | Mahdis BayatOTHER | 0 | Mar 3, 2023 | clinicaltrials |
| NCT05750719 | BRCA and NACT in TNBC Patients(Light-Bright) | completed | — | 136 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT02314156 | Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | completed | Phase 2 | 67 | Northwestern UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02401347 | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | completed | Phase 2 | 21 | Melinda TelliOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04320030 | [18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers(EITHICS) | completed | Phase 2 | 13 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT01846091 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | completed | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT04248179 | The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. | completed | Phase 4 | 36 | Zealand University HospitalOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT03499899 | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | completed | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 17 | Jan 30, 2023 | clinicaltrials |
| NCT03775213 | Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS) | completed | N/A | 322 | Duke UniversityOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT03860740 | Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients(EFIK) | completed | — | 12 | Spanish Breast Cancer Research GroupOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03323658 | Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT04368468 | Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC(MIMOSA) | completed | — | 100 | Institut Claudius RegaudOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 19, 2023source: clinicaltrials